Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics

Abstract

Implementation of the first Generic Drug User Fee Amendments of 2012 (GDUFA I) provided funding to the US Food and Drug Administration (FDA) for modernizing review of the FDA/CDER Generic Drug Program. Under GDUFA I, FDA agreed to reduce the backlog of pending generic Abbreviated New Drug Applications (ANDAs), improve the efficiency of generic drug review, and reduce the number of review cycles with the goal of reducing overall time to approval. This study presents a preliminary analysis of initial filing and regulatory first actions on ANDAs during GDUFA I cohort year 3 (CY3) and cohort year 4 (CY4). It highlights initial successes and areas of improvement in the ANDA review process for both FDA and ANDA applicants to improve the efficiency of providing the public with high-quality, affordable generic drugs.

Keywords

ANDA generic drugs first cycle approval deficiencies

Get full access to this article

View all access options for this article.

References

Generic Drug User Fee Act Reauthorization (GDUFA II), Biosimilar User Fee Act Reauthorization (BsUFA II). https://www.fda.gov/NewsEvents/Testimony/ucm548273.htm. Accessed August 14, 2017.

Association of Accessible Medications. 2017 generic drug access and savings in the United States report. https://www.accessiblemeds.org/resources/blog/2017-generic-drug-access-and-savings-us-report. Accessed October 19, 2017.

Generic Drug User Fee Act I. https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm476659.htm.

Abbreviated New Drug Application (ANDA): Generics. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/default.htm.

Manual of Policies and Procedures Office of Generic Drugs Filing Review of Abbreviated New Drug Applications. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM574493.pdf.

ANDA Submissions – Refuse-to-Receive Standards Guidance for Industry. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm370352.pdf.

ANDA (Generic) drug approvals—previous years. https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/andagenericdrugapprovals/ucm050527.htm.

Product-specific guidances for generic drug development. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm.

Pre-ANDA Program. https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/ucm578012.htm.

10.

Guidance for industry major, minor, and telephone amendments to Abbreviated New Drug Applications. https://www.fda.gov/downloads/Drugs/…/Guidances/ucm072888.pdf.

11.

Srinivasan

Iser

. Common deficiencies in abbreviated new drug applications: Part 1: Drug Substance. Pharm Technol. 2010;34(1):50–59.

12.

Srinivasan

Iser

Gill

. Common deficiencies in abbreviated new drug applications: Part 3: Control of the drug product and stability. Pharm Technol. 2011;3 5(2):58–67.

13.

Guidance for industry Good ANDA submission practices. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf.

14.

MAPP 5241.3 Center for Drug Evaluation and Research manual of policy and procedures. Office of Generic Drugs and Office of Pharmaceutical Quality good ANDA assessment practices. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM591143.pdf